BACKGROUND: Graft hypertrophy is the most common complication of periosteal autologous chondrocyte implantation (p-ACI). PURPOSE: The aim of this prospective study was to analyze the development, the incidence rate, and the persistence of graft hypertrophy after matrix-based autologous chondrocyte implantation (mb-ACI) in the knee joint within a 2-year postoperative course. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Between 2004 and 2007, a total of 41 patients with 44 isolated cartilage defects of the knee were treated with the mb-ACI technique. The mean age of the patients was 35.8 years (standard deviation [SD], 11.3 years), and the mean body mass index was 25.9 (SD, 4.2; range, 19-35.3). The cartilage defects were arthroscopically classified as Outerbridge grades III and IV. The mean area of the cartilage defect measured 6.14 cm(2) (SD, 2.3 cm(2)). Postoperative clinical and magnetic resonance imaging (MRI) examinations were conducted at 3, 6, 12, and 24 months to analyze the incidence and course of the graft. RESULTS: Graft hypertrophy developed in 25% of the patients treated with mb-ACI within a postoperative course of 1 year; 16% of the patients developed hypertrophy grade 2, and 9% developed hypertrophy grade 1. Graft hypertrophy occurred primarily in the first 12 months and regressed in most cases within 2 years. The International Knee Documentation Committee (IKDC) and visual analog scale (VAS) scores improved during the postoperative follow-up time of 2 years. There was no difference between the clinical results regarding the IKDC and VAS pain scores and the presence of graft hypertrophy. CONCLUSION: The mb-ACI technique does not lead to graft hypertrophy requiring treatment as opposed to classic p-ACI. The frequency of occurrence of graft hypertrophy after p-ACI and mb-ACI is comparable. Graft hypertrophy can be considered as a temporary excessive growth of regenerative cartilage tissue rather than a true graft hypertrophy. It is therefore usually not a persistent or systematic complication in the treatment of circumscribed cartilage defects with mb-ACI.
BACKGROUND:Graft hypertrophy is the most common complication of periosteal autologous chondrocyte implantation (p-ACI). PURPOSE: The aim of this prospective study was to analyze the development, the incidence rate, and the persistence of graft hypertrophy after matrix-based autologous chondrocyte implantation (mb-ACI) in the knee joint within a 2-year postoperative course. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Between 2004 and 2007, a total of 41 patients with 44 isolated cartilage defects of the knee were treated with the mb-ACI technique. The mean age of the patients was 35.8 years (standard deviation [SD], 11.3 years), and the mean body mass index was 25.9 (SD, 4.2; range, 19-35.3). The cartilage defects were arthroscopically classified as Outerbridge grades III and IV. The mean area of the cartilage defect measured 6.14 cm(2) (SD, 2.3 cm(2)). Postoperative clinical and magnetic resonance imaging (MRI) examinations were conducted at 3, 6, 12, and 24 months to analyze the incidence and course of the graft. RESULTS:Graft hypertrophy developed in 25% of the patients treated with mb-ACI within a postoperative course of 1 year; 16% of the patients developed hypertrophy grade 2, and 9% developed hypertrophy grade 1. Graft hypertrophy occurred primarily in the first 12 months and regressed in most cases within 2 years. The International Knee Documentation Committee (IKDC) and visual analog scale (VAS) scores improved during the postoperative follow-up time of 2 years. There was no difference between the clinical results regarding the IKDC and VAS pain scores and the presence of graft hypertrophy. CONCLUSION: The mb-ACI technique does not lead to graft hypertrophy requiring treatment as opposed to classic p-ACI. The frequency of occurrence of graft hypertrophy after p-ACI and mb-ACI is comparable. Graft hypertrophy can be considered as a temporary excessive growth of regenerative cartilage tissue rather than a true graft hypertrophy. It is therefore usually not a persistent or systematic complication in the treatment of circumscribed cartilage defects with mb-ACI.
Authors: Upasana Kachroo; Abel Livingston; Elizabeth Vinod; Solomon Sathishkumar; P R J V C Boopalan Journal: Cartilage Date: 2018-08-23 Impact factor: 4.634
Authors: Thomas R Niethammer; Matthias F Pietschmann; Annie Horng; Björn P Roßbach; Andreas Ficklscherer; Volkmar Jansson; Peter E Müller Journal: Knee Surg Sports Traumatol Arthrosc Date: 2013-03-01 Impact factor: 4.342
Authors: A Pelissier; P Boyer; Y Boussetta; G Bierry; W Van Hille; P Hamon; J H Jaeger; P Massin Journal: Knee Surg Sports Traumatol Arthrosc Date: 2013-02-08 Impact factor: 4.342
Authors: Johannes Zellner; Peter Angele; Florian Zeman; Richard Kujat; Michael Nerlich Journal: Clin Orthop Relat Res Date: 2013-09 Impact factor: 4.176
Authors: Charles A Su; Nikunj N Trivedi; Hao-Tinh Le; Lakshmanan Sivasundaram; Travis G Maak; Michael J Salata; James E Voos; Michael Karns Journal: Sports Health Date: 2021-04-22 Impact factor: 3.843